Evidence map›Paper›PMID 32944392›Full record

ReviewCancer biology & medicine2020

Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets.

Yungang Wang, Shouyan Deng, Jie Xu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer biology & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Small-Molecule PROTACs for Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2022
    Review
  5. PROTAC targeted protein degraders: the past is prologue.Nature reviews. Drug discovery · 2022
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Yungang WangInstitutes of Biomedical Sciences, Zhongshan-Xuhui Hospital, and Shanghai Key Laboratory of Medical Epigenetics, Fudan University, Shanghai 200433, China.
Shouyan DengInstitutes of Biomedical Sciences, Zhongshan-Xuhui Hospital, and Shanghai Key Laboratory of Medical Epigenetics, Fudan University, Shanghai 200433, China.
Jie XuInstitutes of Biomedical Sciences, Zhongshan-Xuhui Hospital, and Shanghai Key Laboratory of Medical Epigenetics, Fudan University, Shanghai 200433, China.ORCID 0000-0001-9163-3898
Fudan University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy harness the body's immune system to eliminate cancer, by using a broad panel of soluble and membrane proteins as therapeutic targets. Immunosuppression signaling mediated by ligand-receptor interaction may be blocked by monoclonal antibodies, but because of repopulation of the membrane

Indexed as

AnimalsAntineoplastic Agents, ImmunologicalDrug DiscoveryHumansLigandsLysosomesMolecular Targeted TherapyNeoplasmsProteasome Endopeptidase ComplexProteolysisAntineoplastic Agents, ImmunologicalLigandsProteasome Endopeptidase ComplexCancer immunotherapymembrane proteinPROTACtargeted degradation

Identifiers

PMID32944392
PMCPMC7476092
OpenAlexW3087257528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.